Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$2.98M+1.53%Company Profile
- CEO
- Joseph D. Dowling
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 43
- Beta
- 0.48
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -17.75
Financials
Revenue
$2.98M+1.5%Net Income
$-775.0KEBITDA
$-214.0KFree Cash Flow
$13.0KEPS (diluted)
$-0.00Shares Outstanding (diluted)
205.09M+292.7%Operating Expenses
$1.75MCash & Debt
$266.0KRevenue by Segment (annual)
$100.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $13.79M | $-958.0K | $-0.01 |
| 2024 | $15.71M | $-2.39M | $-0.01 |
| 2023 | $16.00M | $3.10M | $0.02 |
| 2022 | $16.20M | $-8.21M | $-0.06 |
| 2021 | $20.05M | $-15.55M | $-0.14 |
| 2020 | $24.43M | $-22.28M | $-0.22 |
| 2019 | $53.70M | $-16.61M | $-0.17 |
| 2018 | $48.24M | $10.00M | $0.09 |
| 2017 | $20.68M | $-4.90M | $-0.06 |
| 2016 | $11.06M | $-14.14M | $-0.27 |
| 2015 | $11.53M | $-12.23M | $-0.35 |
| 2014 | $10.19M | $-1.31M | $-0.04 |
| 2013 | $2.15M | $-2.30M | $-0.23 |
| 2012 | $0.00 | $-45.6K | $-0.01 |
Valuation
CVSIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+50.00%Social Signal Score
Mentions (3)
- Newsseekingalpha.com·53d ago·Positive
CV Sciences, Inc. (CVSI) Q2 2026 Earnings Call Transcript CV Sciences, Inc. (CVSI) Q2 2026 Earnings Call Transcript
View source ↗ - Newsaccessnewswire.com·55d ago·Negative
CV Sciences Launches PlusHLTH.com, Expanding Its Consumer Platform Beyond Cannabinoids New digital destination brings the Company's Health Intelligence approach to life, helping consumers better understand their needs, discover science-backed solutions, and navigate healthy aging. SAN DIEGO, CA / ACCESS Newswire / August 11, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "our", "us" or "we"), a consumer health company specializing in science-backed natural ingredients and products, today
View source ↗ - Newsaccessnewswire.com·56d ago·Negative
CV Sciences, Inc. to Announce Second Quarter 2026 Results on August 13, 2026 SAN DIEGO, CA / ACCESS Newswire / August 10, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the second quarter ended June 30, 2026, after the stock market closes on Thursday, August 13
View source ↗
Earnings
Mon, Nov 16(in 6 weeks)
Consensus estimate $-0.02 per share
Typical surprise +83.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.00 vs $-0.02beat
- Thu, May 14$-0.00 vs $-0.02beat
- Thu, Mar 26$-0.00 vs $-0.01beat
Estimates and results for CVSI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CVSI officers and directors.
- Bought
- $219k
- Sold
- $1.5m
15 trades
35 trades
- Cheever Charlie E Iiibought
- Cheever Charlie E Iiibought
- Cheever Charlie E Iiibought
- Cheever Charlie E Iiibought
- Cheever Charlie E Iiibought
- Cheever Charlie E Iiibought
- Cheever Charlie E Iiibought
- Cheever Charlie E Iiibought
50 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CVSI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.